BLOG

The BioPharma industry is in rapid flux, shaped by rising tariffs, shifting policies, and new barriers to prescription access. Here’s a quick look at the forces driving change. Source: Time.com The time is now to review your campaigns as FDA oversight ramps up after years of minimal enforcement. Trump’s executive

Discover proven strategies for selecting the right engagement tools for pharmaceutical Virtual Speaker Programs to create memorable peer-to-peer learning experiences that drive results.

Source: FiercePharma President Donald Trump is pressing ahead with plans to impose steep tariffs on imported pharmaceuticals—starting small but ramping up to 250%—in a bid to push drug manufacturing back to the U.S. The move, paired with a revived “most favored nation” pricing policy, has already spurred major pharma companies

Discover proven strategies for selecting the right engagement tools for pharmaceutical Virtual Speaker Programs to create memorable peer-to-peer learning experiences that drive results.

Source: PharmaVoice A new bill led by two independent senators seeks to ban direct-to-consumer (DTC) pharmaceutical advertising, arguing that promotions drive up drug costs and mislead patients. While some support the move as a step toward transparency, critics claim it could limit patient awareness and hinder innovation in healthcare marketing.

Source: Fierce Biotech The FDA is implementing an AI tool named Elsa to expedite drug application reviews, aiming to process initial submissions, sometimes exceeding 500,000 pages and analyzing it in a matter of minutes. Challenges remain as Elsa sometimes produces inaccurate or unreliable responses so all AI-generated outputs will still